What we enable
Enabling cancer diagnostics and precision oncology
DNA methylation + histology
DNA methylation gives a unique molecular fingerprint of the tumour. Histology AI reads the H&E slide a laboratory already has and triages which cases warrant full molecular profiling. Together they lower the barrier to precision oncology.
Precision oncology, accessible to all
On-premise deployment keeps every patient sample local. Your laboratory keeps full control. We never touch patient data.
Individual care & treatment plan
Our models produce a directly actionable report with a well-calibrated confidence score, informing the most appropriate treatment from established options.
Our classifiers are developed under an ISO 13485-compliant quality management system and meet the normative and regulatory requirements applicable to our products.
Two audiences
Built for clinicians and researchers
We serve routine clinical diagnostics and research workflows side by side.
Clinical solutions
For medical professionals
Rapid, objective classification for ambiguous cases. A prospective study of approximately 1,000 brain cancers found a change or refinement in diagnosis in 27% of cases compared with histology alone.
- On-premise deployment: fully local, no access to your systems
- Implementation and validation support in your own setting
- Customisable reports within regulatory constraints
- Support, training and onboarding included
Research · RUO
For researchers
Molecular profiling that aids tumour classification. Guideline authorities including the WHO, EANO and NCCN have integrated methylation profiling into their recommendations.
- Research-use-only access to the full classifier portfolio
- Free for academic research and scientific use
- Any methylation platform, including sequencing
- Collaborations and early-access programmes
Our portfolio & pipeline
From CNS to a growing range of indications
Current portfolio vs. pipeline
Live
Live
Early access
Pipeline
Pipeline
Pipeline
Two modalities, one picture
DNA methylation
Epigenetics
Classifiers trained on large, validated reference cohorts deliver a unique, objective fingerprint of each tumour, robust across laboratories and platforms.
AI on tissue
Digital histopathology
Models that predict methylation class directly from the H&E slide a laboratory already has. Their role is triage: flagging which cases warrant full methylation profiling and which do not, so precision oncology reaches laboratories that cannot run methylation arrays.
Underlying technology. Machine-learning models trained on rigorously annotated cohorts. What makes the approach robust: large reference cohorts, independent validation, and a well-calibrated confidence score for every call.
Trusted by
Find your way
Where to next?
Products
Licensed classifiers installed in your own laboratory, offline, with installation and validation support.
Research
Our technology, the two modalities, and research-use access to the full portfolio.
Company
Our mission, vision and the interdisciplinary team behind precision oncology.
Our ambition
A future where every cancer patient is treated as an individual
Our vision is a world in which all cancer patients are treated appropriately and as individuals, supported by innovative solutions for precision molecular diagnostics.
Reaching it means precision diagnostics that any laboratory can run, not only specialist centres. So we build classifiers that deploy inside a hospital’s own infrastructure, that work with whatever methylation data a laboratory can generate, and that increasingly read the histology it already has, triaging which cases need molecular profiling, and lowering the barrier to precision oncology for laboratories without array capability.
Latest news
A national framework with the NHS Genomic Medicine Service brings methylation-based CNS tumour classification to genomic laboratory services across England, free of charge for all paediatric patients for three years.
Prof. Dr. Dr. med. Felix Sahm joins as Chief Medical Advisor, guiding clinical and medical strategy as the company expands its precision diagnostics portfolio.
A substantial update to the sarcoma tumour classifier, extending precision methylation-based classification beyond tumours of the central nervous system.
